Apogee Announces Formation of Medical Advisory Board

Apogee Technology, Inc. (AMEX: ATA), an emerging
micro-electrical mechanical systems ("MEMS") and nanotechnology
company that designs, develops and markets medical devices and sensors
products, today announced the formation of a Medical Advisory Board
and the appointment of its first three members.
   Herbert Stein, Apogee's Chairman and Chief Executive Officer,
said, "We believe this esteemed board will provide the technical
oversight to help us effectively transition our MEMS based transdermal
delivery products from research, through development, clinical testing
and product approval and release. Dr. Peter Carroll has been appointed
chairman of the advisory board. He has a Ph.D. in immunology and is
the founder of Medlen & Carroll, LLP, a biotechnology patent law firm.
He is joined by Dr. Joachim Kohn, an expert in controlled drug
delivery and the current Director of the New Jersey Center for
Biomaterials, and Dr. Sanford Simon, Professor of Biochemistry, Cell
Biology and Pathology at Stony Brook University and who is involved in
research programs related to cell biology and the development of
vaccines and other therapeutics."
   Dr. Peter G. Carroll, Esq. has approximately ten years of
experience in basic scientific research (1977-1979 Sidney Farber
Cancer Institute; 1979-1983 Tufts Sackler School of Graduate Studies;
1983-1984 Eunice Kennedy Schriver Center) as well as significant
experience in commercial research and development (1984-1986
Travenol-Genentech Diagnostics, Inc.). He also has seven years of
hands on medical laboratory experience (1980-1987 New England Medical
Center). From 1991 to 1993, Dr. Carroll was Vice President of
Commercial Development of a biotechnology startup, now known as Cerus
Corporation, a company formed to address the commercial need for
solutions to blood contamination. Dr. Carroll is the founder of his
own biotechnology patent law firm, Medlen & Carroll, LLP, with offices
in California, Massachusetts, New York, Texas and Wisconsin.
   Dr. Joachim Kohn is a Board of Governors Professor of Chemistry
and Chemical Biology at Rutgers and an Adjunct Associate Professor of
Orthopedics at the New Jersey Medical School. He currently serves as
director of the New Jersey Center for Biomaterials. He is a fellow of
the American Institute for Medical and Biological Engineering (AIMBE)
and served as the secretary-treasurer of the Society for Biomaterials.
He is the principal investigator of an NIH funded postdoctoral
training program in tissue engineering and implant science. His
research interests focus on the development of new biomaterials for
prostheses, implantable drugs, gene delivery systems and tissue
regeneration scaffolds. He has published 200 scientific manuscripts
and reviews, and is listed as an inventor on 37 patents.
   Dr. Sanford R. Simon has over 40 years' of experience in
biochemistry and cell biology as well as applied genetic research. He
has been a Professor of Biochemistry, Cell Biology and Pathology at
Stony Brook since 1997. He joined the faculty at Stony Brook as an
Assistant Professor in 1969 and was promoted to Associate Professor
with tenure in 1975. Dr. Simon was a member of the Board of Directors
of The Collaborative Group from 1995 to 2004. From 1967 to 1969 Dr.
Simon was a Guest Investigator at Rockefeller University. Dr. Simon
received a B.A. in Zoology and Chemistry from Columbia University in
1963, a Ph.D. in Biochemistry from Rockefeller University in 1967, and
studied as a postdoctoral fellow with Nobel Prize winner Max Perutz in
Cambridge, England. Dr. Simon's research efforts, which currently
include development of vaccines and small molecule therapeutics for
biodefense applications, have been funded over the past several years
in part by grants from the National Institutes of Health and the
Department of Defense. Dr. Simon is also the principal investigator on
a project entitled "A Chimeric Method and System for DNA Encryption
and Authentication", which is funded jointly by APDN, Stony Brook's
Center for Biotechnology and the New York State Office of Science,
Technology and Academic Research.

   About Apogee Technology, Inc.

   Apogee Technology designs, develops and markets proprietary sensor
and medical device products using its MEMS and nanotechnology for the
automotive, industrial, consumer and medical markets. The Company has
introduced a family of pressures sensors, under the Sensilica(TM)
brand and is currently developing a MEMS based medical device for
enhanced transdermal drug delivery. Apogee has significant experience
in bringing high-performance and high volume MEMS components to market
quickly. Our objective is to provide value-added and cost-savings
solutions for our customers, and in so doing, to become a global
leader in the field. The Company operates a worldwide marketing and
sales organization and has offices in the US and Japan. For more
information please visit our web site at: http://www.apogeemems.com.

   Sensilica(TM) is a trademark of Apogee Technology, Inc. All other
product names noted herein may be trademarks of their respective
holders. Certain statements made herein that use the words
"anticipate," "hope," "estimate," "project," "intend," "plan,"
"expect," "believe" and similar expressions are intended to identify
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve known and unknown risks and uncertainties, which
could cause the actual results, performance or achievements of the
company to be materially different from those that may be expressed or
implied. Please refer to the company's risk factors as set forth in
the company's filings with the Securities and Exchange Commission,
including its reports on Forms 10-KSB and 10-QSB.